» Articles » PMID: 7362769

Is Tumour Radiosensitization by Misonidazole a General Phenomenon?

Overview
Journal Br J Cancer
Specialty Oncology
Date 1980 Jan 1
PMID 7362769
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The response of 14 mouse tumour sub-lines to the radiosensitizing action of a large single dose of misonidazole (MISO) has been assessed by regrowth delay. In 13 of these, significant enhancement of radiation effect occurred under ambient conditions, indicating sensitization of naturally hypoxic cells. The enhancement observed (SER') varied with the radiation dose, as would be predicted for a mixed oxic/hypoxic cell population. The maximum SER' in these 13 tumours did not depend on histology or regrowth rate. The 14th tumour, a slow-growing sarcoma, was not sensitized under ambient conditions, but showed marked sensitization when clamped to produce acutely hypoxic cells. This is consistent with no hypoxic cells occurring naturally in a sarcoma with a slow rate of growth. Faster-growing variants of this tumour showed radiosensitization under ambient conditions. The slow-growing carcinoma, RH, however, appears to contain hypoxic cells and did show sensitization. The cytotoxic action of MISO was compared with the radiosensitization by administering it after irradiation in 8 of the tumour lines. In 2 tumours no cytotoxicity was observed. In the rest cytotoxicity was significant, but much smaller than the sensitization observed when MISO was administered before irradiation. These regrowth-delay data have been used to calculate hypoxic fractions in 3 ways. Estimates of hypoxic fraction ranged from less than 0.1% in the slow sarcoma to greater than or equal to 30% in several tumours. There is considerable variation in the estimate, according to the technique used.

Citing Articles

Electron paramagnetic resonance oxygen image hypoxic fraction plus radiation dose strongly correlates with tumor cure in FSa fibrosarcomas.

Elas M, Bell R, Hleihel D, Barth E, McFaul C, Haney C Int J Radiat Oncol Biol Phys. 2008; 71(2):542-9.

PMID: 18474313 PMC: 2577780. DOI: 10.1016/j.ijrobp.2008.02.022.


Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo.

Webster L, Hodgkiss R, Wilson G Br J Cancer. 1998; 77(2):227-34.

PMID: 9460993 PMC: 2151217. DOI: 10.1038/bjc.1998.38.


In vivo combination of misonidazole and the chemotherapeutic agent CCNU.

Siemann D Br J Cancer. 1981; 43(3):367-77.

PMID: 7225287 PMC: 2010614. DOI: 10.1038/bjc.1981.57.


In vivo assessment of basic 2-nitroimidazole radiosensitizers.

Williams M, Denekamp J, Minchinton A, Stratford M Br J Cancer. 1982; 46(1):127-37.

PMID: 7104192 PMC: 2011061. DOI: 10.1038/bjc.1982.174.


Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.

Rojas A, Stewart F, Denekamp J Br J Cancer. 1983; 47(1):65-72.

PMID: 6295429 PMC: 2011240. DOI: 10.1038/bjc.1983.8.


References
1.
Asquith J, Watts M, Patel K, Smithen C, Adams G . Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res. 1974; 60(1):108-18. View

2.
Denekamp J, Michael B, Harris S . Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo. Radiat Res. 1974; 60(1):119-32. View

3.
THOMLINSON R, Craddock E . The gross response of an experimental tumour to single doses of x-rays. Br J Cancer. 1967; 21(1):108-23. PMC: 2008074. DOI: 10.1038/bjc.1967.10. View

4.
Denekamp J . The cellular proliferation kinetics of animal tumors. Cancer Res. 1970; 30(2):393-400. View

5.
Denekamp J . The relationship between the 'cell loss factor' and the immediate response to radiation in animal tumours. Eur J Cancer (1965). 1972; 8(3):335-40. DOI: 10.1016/0014-2964(72)90029-1. View